Navigation Links
The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
Date:12/5/2011

NEW YORK, Dec. 5, 2011 /PRNewswire/ -- Levi & Korsinsky is investigating potential claims on behalf of purchasers of the securities of Pacific Biosciences of California, Inc. ("PacBio" or the "Company") (NASDAQ: PACB) concerning possible violations of federal securities laws.

For more information, click here: http://zlk.9nl.com/pacific-biosciences-california-pacb/.

The investigation stems from allegations that the Company failed to disclose the following: (a) that contrary to the Company's claim that the RS system its used for DNA sequencing had a 'market dominating' 99.3 percent base calling accuracy rate, the system's raw-read accuracy rate was in fact between 80 and 84 percent; (b) that as a result of PacBio's inefficient RS system, potential customers would be forced to sacrifice long read length time to obtain increased raw-read accuracy in DNA sequencing; (c) that numerous bugs and flaws in PacBio's RS system caused it to crash frequently; and (d) owing to the aforementioned problems, PacBio's RS system was receiving significant negative feedback.

On September 21, 2011, PacBio disclosed that its operations were threatened by the Company's cash burn and, as a result, the Company would lay off 130 employees and would incur $5 million in related separation expenses.  In reaction to this news, PacBio stock plummeted 25% to close at $4.25 per share.

If you own PacBio stock and wish to obtain additional information about the investigation and your legal rights, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pacific-biosciences-california-pacb.html.

Le
'/>"/>

SOURCE Levi & Korsinsky, LLP
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
2. Elsevier Announces Availability of Urban & Fischer Journal Archives on SciVerse ScienceDirect
3. Drug-Free BLOOD PRESSURE Control & Medical "Take-Away" Treatment are Potential Win-Win Solutions in Health Care
4. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
5. S&P Capital IQ Picks Celgene Focus Stock of the Week
6. Sandell Asset Management Seeks Sale of Rubicon & Tenon, Expansion of Board
7. Wound Management Technologies to Present at AdvaMed 2011; Conferences Featured Speakers to Include President George W. Bush & HHS Secretary Kathleen Sebelius
8. AtheroNova Rodman & Renshaw Presentation Now Online at www.AtheroNova.com
9. Building, Validating & Maintaining Controlled Environment Facilities is Focus of Oct. 18th Seminar in Boston Hosted by Microtest Laboratories
10. Johnson & Johnson Symposium Honors 2011 Recipient of The Dr. Paul Janssen Award for Biomedical Research
11. Palatin Technologies, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... in German . ... dots in a semiconductor layer. Quantum dots are small structures ... If a short laser pulse is fired at the photonic ... experiences a change in the electromagnetic field around it. This ... light by the dot. As soon as the refractive index ...
(Date:9/30/2014)... Using a bio-mimicking analog of one of nature,s ... international research team led by Alejandro Briseno of ... major step in developing long-sought polymer architecture to ... use in electronic devices. , Briseno, with ... others at Stanford University and Dresden University of ...
(Date:9/30/2014)... 30, 2014 Shimadzu Scientific Instruments ... easy-to-use and highly precise tool for measuring displacement ... elongation. With 1000-mm maximum movement distance, the DSES-1000 ... a gauge length of 10 mm. In addition, ... above 50-mm stroke and within +/- 100 µm ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Proove ... medicine, is excited to announce a new genetic test ... The Proove Pain Perception Test will provide physicians ... and why pain tolerance levels are stratified between individuals. ... identify whether a person has a genetic predisposition that ...
Breaking Biology Technology:Ultrafast remote switching of light emission 2Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3
... - YM BioSciences Inc. (NYSE Amex: YMI ... company that identifies and advances a diverse portfolio ... development, today reported that its licensee for nimotuzumab, ... has commenced enrollment of a Phase II trial ...
... and to Complete Current Phase 3 Trial of Naturlose(R) ... June 23 Spherix Incorporated (Nasdaq: SPEX ... a provider of technical and regulatory consulting services to ... it has received its first full-scale production batch of ...
... Medical Device & Diagnostic Industry Magazine,s 30 Years, 30 Devices Special ... 23 Medical Device and Diagnostic Industry has recognized ... a leader in infusion therapy and pain management as well as ... as being among the most influential medical devices of the last ...
Cached Biology Technology:YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 2YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 3YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 4YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 5Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 2Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 3Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 4B. Braun Medical Inc. Recognized by Industry for Manufacturing Influential Medical Devices 2B. Braun Medical Inc. Recognized by Industry for Manufacturing Influential Medical Devices 3B. Braun Medical Inc. Recognized by Industry for Manufacturing Influential Medical Devices 4
(Date:9/29/2014)... Washington, DC Monday, September 29: Between 1970 ... and fish around the globe dropped 52 percent, ... by World Wildlife Fund (WWF). This biodiversity loss ... increasing resource use of high-income countries. , In ... the report,s data point to other warning signs ...
(Date:9/29/2014)... school? According to a new Food and Brand Lab ... can increase participation in the National School Lunch Program ... vegetables by 16%! , Chefs Move to Schools (CMTS), ... chefs with schools in order to provide nutrition instruction ... service workers. , A CMTS event was held in ...
(Date:9/29/2014)... team says recently identified radiation detection properties of a ... for homeland security and medical advances. , In a ... of Optics Letters , UT Arlington Physics Professor ... to fabricate transparent nanoscintillators by heating nanoparticles composed of ... formed. A scintillator refers to a material that ...
Breaking Biology News(10 mins):Half of global wildlife lost, says new WWF report 2Chefs move to schools can increase school meal participation and vegetable intake among students 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3
... y MUNICH, 7 de noviembre de 2012 Bausch + ... ejercitación de su opción de compra de todas las acciones ... Vision GmbH (TPV), una destacada compañía láser de oftalmología. ... de una sociedad mixta entre Bausch + Lomb y 20/10 ...
... 2012 Bausch + Lomb, a empresa global de saúde ... as ações em circulação e sem controle da Technolas ... A Technolas Perfect Vision foi criada em 2009 ... + Lomb e a 20/10 PERFECT VISION AG para desenvolver ...
... well known for attacking a protein associated with the ... it also degraded a different protein that triggers blood ... a key challenge in the battle against cancer, according ... in the University of Leeds, Faculty of Biological Sciences., ...
Cached Biology News:Bausch + Lomb adquiere Technolas Perfect Vision GmbH 2Bausch + Lomb adquiere Technolas Perfect Vision GmbH 3Bausch + Lomb adquiere Technolas Perfect Vision GmbH 4Bausch + Lomb prestes a adquirir a Technolas Perfect Vision GmbH 2Bausch + Lomb prestes a adquirir a Technolas Perfect Vision GmbH 3Bausch + Lomb prestes a adquirir a Technolas Perfect Vision GmbH 4Breast cancer drug could halt other tumors 2
Rabbit polyclonal to hnRNP-U...
... iTaq DNA polymerase is ... suitable for both conventional and ... is supplied at a concentration ... and includes 250 units polymerase, ...
... (E.C. 3.1.21.1) is a nonspecific endonuclease that ... functions by hydrolyzing phosphodiester linkages, producing mono ... 3'-hydroxyl group. Ambion's RNase-free DNase I is ... recommended to degrade DNA in the presence ...
RABBIT ANTI RHEB (IN) Immunogen: A 15 amino acid peptide located in the central region of human Rheb....
Biology Products: